-transparent.png){kind=logo}
Preoperative serum CEA and CA 19-9 levels in 158 patients with gastric cancer were analyzed with respect to prognostic factors, using univariate and multivariate analysis. The incidence of high preoperative levels of both CEA and CA 19-9 was 10.1% (16/158). 13.9% (22/158) showed high CEA levels and normal CA 19-9 levels, whereas the reverse was true in 16.5% (26/158). Neither marker showed a high level in 59.5% (94/158). The multivariate analysis showed that in addition to tumor stage, the depth of invasion, liver metastasis and peritoneal dissemination, combination assays of preoperative serum CEA and CA 19-9 levels were an independent prognostic factor. Combination assays of preoperative serum CEA and CA 19-9 will allow us to conduct a more careful postoperative follow-up of high-risk patients, and also help determine the optimum adjuvant chemotherapy.
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
January 2010,
Hepato-gastroenterology,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
October 2008,
Advances in therapy,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
August 1995,
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
January 1997,
Anticancer research,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
January 1987,
Acta gastro-enterologica Belgica,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
January 2011,
Hepato-gastroenterology,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
January 1999,
Hepato-gastroenterology,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
March 2021,
Cancers,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
August 1997,
American journal of clinical oncology,
Y Ikeda, and
H Oomori, and
N Koyanagi, and
M Mori, and
T Kamakura, and
S Minagawa, and
H Tateishi, and
K Sugimachi
January 2000,
Anticancer research,
